Albert David LimitedALBERTDAVDCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Sep 2024 2 quarters of data

₹831.00

MCap ₹474 Cr

Albert David Limited — Stock analysis & AI research Albert David Limited — Seasonality — best & worst months Albert David Limited — Technical setup — score, trend, support & resistance Albert David Limited — Live exchange announcements

🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹98 Cr

Sales · Sep 2024

₹6 Cr

Operating Profit · Sep 2024

6.3%

OPM % · Sep 2024

₹18 Cr

Net Profit · Sep 2024

₹31.67

EPS · Sep 2024

📝 Albert David Limited — results explained

Quarter ended September 2024 (Q2 FY25)

Albert David Limited reported revenue of ₹98 crore for the quarter ended September 2024 (Q2 FY25), and up 10.2% sequentially over the June 2024 quarter.

Net profit stood at ₹18 crore. Earnings per share (EPS) came in at ₹31.67.

Operating profit stood at ₹6 crore — an operating margin (OPM) of 6.3%.

Valuation snapshot

At the current price of ₹831.00, ALBERTDAVD has a market capitalisation of ₹474 crore.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 25th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 62.24%, foreign institutional investors (FIIs) 0.60%, domestic institutional investors (DIIs) 1.64%, public shareholders 35.53% of Albert David Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹474 Cr

Current Price ?

₹831.0

P/E ?

N/A

Industry P/E ?

37.20

P/B ?

1.21

P/S ?

N/A

P/FCF ?

-13.17

Enterprise Value ?

₹504 Cr

EV/EBITDA ?

N/A

PEG ?

N/A

Earnings Yield ?

N/A

Dividend Yield ?

N/A

Profitability & Returns

Sales (TTM) ?

N/A

OPM ?

N/A

Profit after tax (TTM) ?

N/A

EPS (TTM) ?

N/A

ROCE ?

1.0%

ROE ?

N/A

ROA ?

N/A

Growth

Sales — latest qtr ?

₹98 Cr

PAT — latest qtr ?

₹18 Cr

YoY qtr sales growth ?

N/A

YoY qtr profit growth ?

N/A

Sales growth (3y) ?

N/A

Sales growth (5y) ?

N/A

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

₹30 Cr

Debt to Equity ?

0.08

Interest Coverage ?

N/A

Current Ratio ?

N/A

Ownership

Promoter holding ?

62.24%

Change in promoter holding ?

0.01%

Pledged percentage ?

N/A

Market

Return 3 months ?

18.7%

Return 6 months ?

15.9%

🗓️ Quarterly results (2 quarters · ₹ Cr)

same fiscal quarter as Sep bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Jun 2024	Sep 2024	YoY %	QoQ %
Sales	89	98	—	+10.2%
Operating Profit	1	6	—	+608.7%
Other Income	23	21	—	-10.5%
Interest	0	0	—	-37.7%
Depreciation	2	2	—	-6.5%
Profit Before Tax	22	25	—	+13.9%
Net Profit	19	18	—	-4.1%
EPS	33.02	31.67	—	-4.1%
OPM %	1.0%	6.3%	—	+530.0%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	6	6	6	6	+0.0%
Reserves	306	377	387	386	-0.3%
Borrowings	5	3	12	30	+150.0%
Other Liabilities	106	112	107	98	-8.4%
Total Liabilities	423	498	511	519	+1.6%
Fixed Assets	80	83	99	100	+1.0%
CWIP	3	7	2	21	+950.0%
Investments	193	273	260	243	-6.5%
Other Assets	148	135	151	155	+2.6%
Total Assets	423	498	511	519	+1.6%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	11	46	-28	-8	+71.4%
Cash from Investing Activity	-5	-33	23	-4	-117.4%
Cash from Financing Activity	-6	-8	0	12	—
Net Cash Flow	-1	4	-5	-0	+100.0%
Free Cash Flow	6	35	-43	-36	+16.3%
CFO/OP	59%	131%	-629%	-49%	+92.2%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	32	30	29	37	+27.6%
Inventory Days	149	126	201	187	-7.0%
Days Payable	95	98	118	104	-11.9%
Cash Conversion Cycle	87	58	112	120	+7.1%
Working Capital Days	14	-13	6	247	+4016.7%
ROCE %	17%	28%	6%	1%	-83.3%

👥 Shareholding (latest 6 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026	% Chg
Promoters	62.23%	62.23%	62.23%	62.23%	62.24%	62.24%	+0.0%
FIIs	0.84%	0.60%	0.60%	0.58%	0.57%	0.60%	+5.3%
DIIs	1.65%	1.65%	1.65%	1.65%	1.64%	1.64%	+0.0%
Public	35.27%	35.50%	35.51%	35.52%	35.56%	35.53%	-0.1%
No. of Shareholders	15,070	14,666	13,967	13,555	13,155	12,709	-3.4%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	AKUMS Akums Drugs	₹784.55	12,012	41.2	4,502	293	12.6%	6.5%	5.9%	-25.5%	13.9%	56.1%
2	STAR Strides Pharma	₹1,085.00	10,001	26.7	3,636	389	25.4%	10.7%	-20.4%	99.0%	11.2%	50.0%
3	BLUEJET Blue Jet	₹565.05	9,802	36.9	884	265	36.3%	30.0%	8.0%	0.7%	-17.5%	-14.3%
4	AARTIPHARM Aarti Pharmalabs	₹828.30	7,511	36.1	1,957	208	22.0%	10.6%	1.5%	-26.9%	42.4%	39.2%
5	SUPRIYA Supriya Lifescience	₹870.30	7,004	35.3	873	198	33.2%	22.7%	18.9%	11.1%	30.8%	-30.9%
6	INNOVACAP Innova Captab	₹1,199.30	6,863	13.8	5,779	497	14.6%	8.6%	355.1%	277.4%	33.9%	42.3%
7	MOREPENLAB Morepen Laboratories	₹123.35	6,759	48.0	1,951	141	9.4%	7.2%	-0.3%	-18.3%	34.1%	394.0%
8	IOLCP IOL Chemicals	₹201.19	5,905	35.2	2,523	168	12.3%	6.7%	11.5%	36.6%	37.1%	89.8%
9	FDC FDC	₹350.20	5,702	19.5	2,191	291	15.3%	13.3%	3.0%	4.8%	3.0%	9.5%
10	NOVARTIND Novartis India	₹2,257.80	5,575	57.0	371	97	27.6%	26.2%	-0.3%	-6.9%	18.2%	14.3%
11	ORCHPHARMA Orchid Pharma	₹1,058.75	5,370	236.9	812	22	5.1%	2.7%	-11.9%	-76.4%	0.2%	25.4%
12	RPGLIFE RPG Life	₹2,865.90	4,740	39.7	735	120	21.1%	16.3%	8.4%	-36.9%	15.8%	16.3%
13	ZOTA Zota Health	₹1,232.70	4,269	—	609	-104	0.6%	-17.1%	84.6%	-29.8%	66.9%	-213.9%
14	GUFICBIO Gufic Biosciences	₹419.85	4,210	57.3	974	74	16.9%	7.6%	14.7%	-9.1%	14.9%	86.0%
15	UNICHEMLAB Unichem Laboratories	₹526.70	3,708	12.2	2,308	305	9.9%	13.2%	6.2%	74.1%	20.1%	496.1%
16	INDSWFTLAB Ind-Swift Laboratories	₹374.00	3,252	55.4	665	57	9.0%	8.6%	235.3%	10.1%	32.3%	-88.7%
17	ADVENZYMES Advanced Enzyme	₹293.25	3,249	19.8	750	172	29.8%	22.9%	17.1%	29.6%	2.1%	-4.6%
18	SOLARA Solara Active	₹667.00	3,218	85.6	1,535	37	15.2%	2.4%	6.6%	-1470.4%	33.1%	381.8%
19	DCAL Dishman Carbogen	₹162.08	2,541	157.6	2,902	16	16.7%	0.6%	8.1%	2655.7%	-4.3%	-351.7%
20	INDOCO Indoco Remedies	₹254.59	2,347	n/m	1,872	3	8.8%	0.2%	10.7%	-26.5%	6.5%	280.0%
21	PANACEABIO Panacea Biotec	₹368.55	2,257	—	673	-9	0.3%	-1.3%	14.4%	17.9%	19.7%	-44.4%
22	REMUS Remus Pharma.	₹1,911.30	2,252	91.1	94	25	31.7%	26.7%	—	—	13.3%	21.4%
23	SAKAR Sakar Healthcare	₹987.40	2,167	61.0	272	36	28.5%	13.3%	41.9%	71.8%	38.4%	120.2%
24	JAGSNPHARM Jagsonpal Pharmaceuticals	₹227.53	1,501	33.3	294	45	20.7%	15.4%	6.9%	-22.2%	8.5%	20.4%
25	ALBERTDAVD Albert David	₹845.50	483	21.4	364	23	7.6%	6.4%	-96.4%	-100.0%	42.3%	300.0%

❓ Frequently asked questions

What was Albert David Limited's revenue in Q2 FY25?